© 2022 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
August 28, 2008
The benefits of implantable cardioverter-defibrillators (ICDs) have been shown in randomized clinical trials. The factors that affect the risk–benefit ratio in a community setting, however, have not been evaluated.
Phase 3 Data Show Isatuximab Offers Progression Free Survival for Multiple Myeloma
Gut Microbiota Dybiosis May Be Linked to Rheumatic Disease
Edward Chen, MD: Amassing Data on Sarcoidosis Prevalence in Rural and Suburban Areas in the US